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Aims We compared patient-reported treatment satisfaction and the economic impact of anticoagulation therapy with
rivaroxaban vs. vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation undergoing elective
cardioversion procedures.
Methods
and results
The current study is a post hoc analysis of the prospective, multicentre X-VeRT (EXplore the efficacy and safety of once-
daily oral riVaroxaban for the prevention of caRdiovascular events in subjects with non-valvular aTrial fibrillation sched-
uled for cardioversion) trial. Patient-reported treatment satisfaction with anticoagulation therapy was assessed using
the Treatment Satisfaction Questionnaire for Medication version II in seven countries (US, UK, Canada, Germany,
France, Italy, and the Netherlands). An economic model was also developed to estimate the impact of postponed
cardioversions for two countries (UK and Italy). This model estimated the total costs of cardioversion, taking into
consideration the costs for drug therapy (including extended treatment duration due to cardioversion postponement),
international normalized ratio monitoring of VKAs, the cardioversion procedure, and rescheduling the procedure.
These costs were linked to the respective X-VeRT study data to estimate the total costs. Patients receiving rivaroxaban
in the delayed cardioversion group had significantly higher scores for Convenience, Effectiveness, and Global satisfac-
tion (81.74 vs. 65.78; 39.41 vs. 32.95; and 82.07 vs. 66.74, respectively; P, 0.0001). Based on the total patient popu-
lation included in the treatment satisfaction substudy (n ¼ 632) in the delayed cardioversion group in X-VeRT, the use
of rivaroxaban was estimated to result in a saving of £421 and E360 per patient in UK and Italian settings, respectively.
Conclusion The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared
with that of VKA.
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Introduction
Atrial fibrillation (AF) is the most frequently encountered sustained
cardiac arrhythmia, with a prevalence of 1.5–2% in the general
population.1 Owing to the well-documented risk of stroke and
other complications associated with AF, patients commonly undergo
cardioversion to restore sinus rhythm;2 however, in the absence
of adequate anticoagulation, cardioversion is associated with a
5–7% risk of thromboembolic complications.3 Therefore, at least
3 weeks of effective anticoagulation with a vitamin K antagonist
(VKA) has traditionally been recommended before cardioversion,
in addition to at least 4 weeks of oral anticoagulation after the pro-
cedure. Transoesophageal echocardiogram-guided cardioversion is
also recommended by guidelines as an alternative to 3-week pre-
procedural anticoagulation; this enables physicians to rule out a left
atrial thrombus and thereby expedite cardioversion.1
Limitations associated with the use of VKAs can be challenging for
the physician and impose restrictions on patients’ daily activities.
Inadequate pre-procedural anticoagulation-related issues are re-
sponsible for .50% of cancellations of planned cardioversions,
thereby imposing a cost burden.4 In addition, the delay in the time
taken to achieve adequate pre-procedural anticoagulation with
VKAs may also negatively impact patient convenience and the over-
all treatment satisfaction.
Health economic evaluations, such as budget impact analyses,
can assist physicians in making informed decisions regarding the
cost-effectiveness of a drug. Although the cost of rivaroxaban ex-
ceeds that of warfarin, decision-makers are increasingly interested
in the overall budget impact. The main outcome of the X-VeRT
(EXplore the efficacy and safety of once-daily oral riVaroxaban
for the prevention of caRdiovascular events in subjects with non-
valvular aTrial fibrillation scheduled for cardioversion) study sug-
gests that rivaroxaban provides simple and reliable anticoagulation
in this setting compared with VKAs;5 this finding could potentially
reduce the number of cancelled or postponed cardioversion pro-
cedures in clinical practice, thus increasing patient satisfaction and
reducing costs.
The aim of this post hoc analysis of the X-VeRT trial was to com-
pare patient-reported treatment satisfaction and the economic
impact of anticoagulation therapy for rivaroxaban vs. VKAs in
elective cardioversion procedures.5
Methods
X-VeRT study
X-VeRT explored the efficacy and safety of once-daily rivaroxaban
(20 mg, or 15 mg in patients with moderate renal impairment, i.e.
creatinine clearance 30–49 mL/min inclusive), compared with
dose-adjusted VKA for the prevention of cardiovascular events in
patients aged ≥18 years with non-valvular AF lasting .48 h, or for an
unknown duration, scheduled for elective cardioversion.5 X-VeRT was
designed to reflect guideline-recommended treatment strategies, with
rivaroxaban being investigated in the settings of early cardioversion after
prior VKA treatment or with transoesophageal echocardiogram guid-
ance and delayed cardioversion with ≥3 weeks of pre-procedural
anticoagulation.6
Rivaroxaban administered de novo, or as ongoing therapy, or as a
replacement for VKAs or another anticoagulant agent, was associated
with thromboembolic and bleeding risks that were low and similar to
those observed with VKA treatment—an observation that applied to
both early and delayed cardioversion strategies. Overall, the time
between randomization and cardioversion was significantly shorter
(delayed strategy) in patients assigned to rivaroxaban, compared with
those receiving a VKA [22 (interquartile range: 21–26) days vs. 30
(interquartile range: 23–42) days, P, 0.001].5
Assessment of treatment satisfaction
Patient-reported treatment satisfaction with anticoagulation therapy
was assessed as an exploratory endpoint in the X-VeRT study. The
Treatment Satisfaction Questionnaire for Medication version II
(TSQM II) is available in seven countries (US, UK, Canada, Germany,
France, Italy, and the Netherlands). Patients from these countries com-
pleted the questionnaire at the end of the treatment period (i.e. 42 days
after cardioversion). Data were analysed in accordance with predefined
criteria.7 The TSQM II is a widely used generic measure of treatment
satisfaction,8 and it has been validated in patients receiving anticoagu-
lants for the treatment of acute symptomatic deep vein thrombosis
(DVT).9 The questionnaire consists of 11 items representing four sub-
scales: Convenience, Effectiveness, Global satisfaction, and Side-
effects.8,9 Patient-reported outcomes were rated on five- and seven-
point Likert scales ranging from ‘Extremely dissatisfied’ to ‘Extremely
satisfied’. Scores for Convenience, Effectiveness, Global satisfaction,
and Side-effects were between 0 and 100 (see Supplementary material
online, Table S1). Higher scores indicate higher convenience, better
effectiveness, higher global satisfaction, and fewer side-effects.9
Budget impact model analyses
An economic model has been developed to estimate the impact of post-
poned cardioversions on a hospital budget. This model estimates the
total costs per treatment of a cardioversion, and components consid-
ered are: costs for drug therapy (including extended treatment duration
due to postponing), international normalized ratio (INR) monitoring,
cardioversion procedure, and rescheduling. These costs were linked
to the respective clinical X-VeRT data (a delayed cardioversion strategy
in which patients received pre-procedural anticoagulation for ≥3
weeks)5 to estimate the total costs. To estimate the budget impact of
What’s new?
† Rivaroxaban was associated with significantly higher treat-
ment satisfaction (Convenience, Effectiveness, and Global
satisfaction) compared with vitamin K antagonists in
patients with non-valvular atrial fibrillation scheduled to
undergo cardioversion.
† Application of X-VeRT data using an economic model
showed that the use of rivaroxaban in place of warfarin in
the delayed cardioversion group could result in a saving of
£421 per patient in the UK setting and E360 per patient
in Italy.
† Based on the total patient population (n ¼ 632) in the
delayed cardioversion group in X-VeRT, the estimated cost
savings may equate to over £260 000 in the UK and
E228 000 in Italy—equivalent to the cost of 318 and 340
cardioversion procedures, respectively.
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rivaroxaban vs. VKA, total costs were then compared between the
treatment groups.
Clinical data from X-VeRT
To estimate the cost of drug therapy, the total treatment duration was
assessed. According to the protocol, at least 63 days of therapy was
required in the delayed strategy arm: 21 days prior to and 42 days after
the cardioversion. Because of the higher proportion of postponed car-
dioversions in the warfarin arm, the median time to cardioversion, and
thus the treatment duration, was 8 days longer than for rivaroxaban-
treated patients (30 vs. 22 days).5 This additional time was considered
in the calculation of the total treatment duration. Another component
of the therapy costs is the number of INR monitoring visits, estimated by
the numbers of INR values per patient pre- and post-cardioversion in
the X-VeRT study (see Results).
The model also considers the percentage of cardioversions that are
postponed on the scheduled day (day of planned cardioversion).
From the overall X-VeRT data (delayed cardioversion strategy), 64%
of planned cardioversions (n ¼ 215) were not conducted in warfarin-
treated patients. In 75% of these, the reason was inadequate anticoagu-
lation.5 On the basis of X-VeRT study design, it was assumed that
physicians only became aware of the INR values on the scheduled
day, i.e. all of these cardioversions were postponed on the scheduled
day. In the rivaroxaban group, only 23% of cardioversions were not con-
ducted as planned.5 We assumed that 75% of the cardioversions were
postponed on the scheduled day in the rivaroxaban group, which is a
highly conservative estimate. Overall, of the total planned cardioversion
procedures, 48% (64 × 0.75%) and 17% (23 × 0.75%) of cardioversions
had to be rescheduled on the scheduled day in warfarin- and
rivaroxaban-treated patients, respectively.
Unit costs
The clinical results described above were linked to the respective unit
costs for drug therapies, INR monitoring, and cardioversion. To be
able to compare the budget impact between countries, we selected
the UK and Italy for the economic analysis; owing to the lack of data
stemming from other countries, the current analysis is focused only
on those countries for which robust figures were available. Table 1 lists
the unit costs used in the budget impact model for these two countries.
Combining clinical data and unit costs
To estimate the total cost per patient of the procedure, the total treat-
ment duration—including the extended median duration in the warfarin
arm—was linked to the respective unit costs for warfarin (it was
assumed that warfarin is used at a daily dose of 4.5 mg) and rivaroxaban.
International normalized ratio monitoring costs were estimated by
multiplying the estimated frequency with the respective costs for one
monitoring visit. The total cost of cardioversion procedures was
included. It was assumed that the cost of cardioversions postponed
on the scheduled day was a loss to the hospital, because the procedure
slot could not be filled with another patient at short notice. In addition,
the average costs of the postponed cardioversions, i.e. 48 and 17%
for warfarin- and rivaroxaban-treated patients, respectively, were
added. The total costs were calculated as the sum of these single
components.
Statistical methods
With respect to the quantification of the treatment satisfaction out-
comes, all statistical tests were performed at a two-sided 5% type I error
level. No adjustments for multiple comparisons were done, and thus, all
P-values were considered as nominal P-values.
An exploratory analysis of variance, including for fixed-factors treat-
ment, cardioversion strategy, and their interaction, was performed for
each subscale of the TSQM II score (Convenience, Effectiveness, Global
satisfaction, and Side-effects). Adjusted means and 95% confidence
intervals for rivaroxaban vs. VKA and early vs. delayed cardioversion
strategy were calculated.
Results
Demographics and clinical characteristics
Of the 1504 patients who underwent randomization within the
main X-VeRT trial, a total of 705 patients were included in the
intention-to-treat population and participated in the treatment
satisfaction substudy; 472 (67%) of these patients were assigned
to receive rivaroxaban and 233 (33%) VKA.
Demographics and clinical characteristics in the overall popula-
tion and by cardioversion strategy are summarized in Table 2. Over-
all, 44% of the study population were aged 65 years or under, and
.60% of the population had a high CHA2DS2-VASc stroke risk
score and persistent AF. In general, characteristics were well
balanced across both study groups, with the exception of congestive
heart failure and hypertension; 8% more patients with a history of
congestive heart failure were in the rivaroxaban group [95 (20.1%)
rivaroxaban vs. 29 (12.4%) VKA], whereas 6% more patients with
a history of arterial hypertension were in the VKA group [313
(66.3%) rivaroxaban vs. 168 (72.1%) VKA]. Similarly, slightly more
patients in the treatment satisfaction substudy had arterial hyperten-
sion than in the overall X-VeRT population (substudy: rivaroxaban
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Table 1 X-VeRT delayed cardioversion strategy-based budget impact model inputs for the UK and Italy
UK Italy
Rivaroxaban Warfarin Rivaroxaban Warfarin
Drug costs (per day) £2.1010 £0.1111 E2.0912 E0.0713
INR monitoring N/A £21.55 (first monitoring)
£24.96 (subsequent monitoring)
N/A 26.09
Cost of cardioversion £83510,14 E676 E662
INR, international normalized ratio; N/A, not applicable. X-VeRT, EXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in
subjects with non-valvular aTrial fibrillation scheduled for cardioversion.
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66% and VKA 72% vs. X-VeRT population: rivaroxaban 65% and
VKA 68%). It was estimated that the INR of warfarin-treated pa-
tients was monitored approximately six times pre-cardioversion
(i.e. 5.7 visits) and five times post-cardioversion (i.e. 4.7 visits).
Treatment satisfaction
Overall, patients reported greater satisfaction in the rivaroxaban
group compared with the VKA group: TSQM II subscale
scores for Convenience, Effectiveness, and Global satisfaction
were 80.32 vs. 66.71, 38.76 vs. 34.37, and 81.67 vs. 67.46, respect-
ively (P, 0.001 for all interactions) when rivaroxaban was com-
pared with VKA therapy. For Side-effects, rivaroxaban compared
favourably with the VKA group (61.37 vs. 58.05, P ¼ 0.061; Table 3).
Rivaroxaban patients in the delayed cardioversion strategy group
showed significantly higher adjusted means compared with standard
therapy for the following subscales: Convenience, Effectiveness,
and Global satisfaction (81.74 vs. 65.78, 39.41 vs. 32.95, and
82.07 vs. 66.74, respectively; P, 0.0001 for all interactions).
Numerically higher adjusted means for Side-effects were reported
in rivaroxaban patients in the delayed cardioversion strategy
group compared with those in the early group (61.82 vs. 59.27,
P ¼ 0.3331; Table 4).
Budget impact model
The total cardioversion procedure cost per patient receiving either
rivaroxaban or warfarin in the UK and Italian settings is presented in
Table 5. Application of X-VeRT data in the UK setting showed that
the use of rivaroxaban in place of warfarin could result in a saving of
£421 per patient. This means that for 632 patients (rivaroxaban-
treated patients in the delayed cardioversion strategy group),5 the
use of rivaroxaban in place of warfarin could result in a saving of
over £260 000, which is equivalent to the cost of 318 cardiover-
sion procedures in the UK. Similarly, in Italy, the relevant cardiover-
sion cost saving per patient was shown to beE360, meaning that for
632 patients, E228 000 could be saved, equating to 340 cardio-
version procedures in Italy.
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Table 2 Demographics (intention-to-treat population)
Total TSQM population by
treatment (N5 705)
Early cardioversion (N5 395) Delayed cardioversion (N5 310)
Rivaroxaban
(N 5 472)
VKA
(N5 233)
Rivaroxaban
(N 5 272)
VKA
(N 5 123)
Rivaroxaban
(N 5 200)
VKA
(N5 110)
Gender: female, n (%) 125 (26.5) 61 (26.2) 71 (26.1) 38 (30.9) 54 (27.0) 23 (20.9)
Age group (years)
,65 202 (42.8) 109 (46.8) 117 (43.0) 52 (42.3) 85 (42.5) 57 (51.8)
65–74 174 (36.9) 82 (35.2) 98 (36.0) 49 (39.8) 76 (38.0) 33 (30.0)
≥75 96 (20.3) 42 (18.0) 57 (21.0) 22 (17.9) 39 (19.5) 20 (18.2)
Medical history, n (%)
Prior stroke/TIA or SE 36 (7.6) 20 (8.6) 19 (7) 6 (4.9) 17 (8.5) 14 (12.7)
Congestive HF 95 (20.1) 29 (12.4) 61 (22.4) 20 (16.3) 34 (17.0) 9 (8.2)
Arterial hypertension 313 (66.3) 168 (72.1) 197 (72.4) 92 (74.8) 116 (58.0) 76 (69.1)
Diabetes mellitus 115 (24.4) 56 (24.0) 72 (26.5) 36 (29.3) 43 (21.5) 20 (18.2)
Atrial fibrillation, n (%)
First diagnosed 88 (18.6) 38 (16.3) 36 (13.2) 18 (14.6) 52 (26.0) 20 (18.2)
Paroxysmala 76 (16.1) 50 (21.5) 55 (20.2) 35 (28.5) 21 (10.5) 15 (13.6)
Persistenta 299 (63.3) 138 (59.2) 175 (64.3) 66 (53.7) 124 (62.0) 72 (65.5)
Long-standing persistenta 7 (1.5) 4 (1.7) 5 (1.8) 2 (1.6) 2 (1.0) 2 (1.8)
CHADS2 score, n (%)
Low: 0 100 (21.2) 43 (18.5) 42 (15.4) 16 (13.0) 58 (29.0) 27 (24.5)
Moderate: 1 177 (37.5) 103 (44.2) 107 (39.3) 57 (46.3) 70 (35.0) 46 (41.8)
High: ≥2 195 (41.3) 87 (37.3) 123 (45.2) 50 (40.7) 72 (36.0) 37 (33.6)
CHA2DS2-VASc score, n (%)
Low: 0 (or 1, if female only) 64 (13.6) 25 (10.7) 25 (9.2) 9 (7.3) 39 (19.5) 16 (14.5)
Moderate: 1 (except for
female alone)
95 (20.1) 52 (22.3) 56 (20.6) 25 (20.3) 39 (19.5) 27 (24.5)
High: ≥2 313 (66.3) 156 (67.0) 191 (70.2) 89 (72.4) 122 (61) 67 (60.9)
CHADS2, Congestive heart failure, Hypertension, Age (≥75 years), Diabetes mellitus, Stroke/transient ischaemic attack; CHA2DS2-VASc, Congestive heart failure/left ventricular
dysfunction, Hypertension, Age ≥75 years, Diabetes mellitus, Stroke/transient ischaemic attack/thromboembolism, Vascular disease (prior myocardial infarction or aortic plaque),
Age 65–74 years, Sex category (female); HF, heart failure; SE, systemic embolism; TIA, transient ischaemic attack; TSQM, Treatment Satisfaction Questionnaire for Medication
version II; VKA, vitamin K antagonist.
aThe classification of the different types of atrial fibrillation was made by the investigator, and the decision to proceed with cardioversion was also left at their discretion.
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Discussion
This substudy of X-VeRT compared patient-reported treatment
satisfaction and the economic impact of anticoagulation for patients
receiving rivaroxaban as an oral fixed-dose regimen vs. standard of
care in elective cardioversion procedures. Results are based on the
findings from the X-VeRT study and a treatment satisfaction substu-
dy.5 For the budget impact simulation model, these results were
combined with local cost figures.7
The X-VeRT study showed that rivaroxaban provided important
practical advantages over VKAs, with significantly more patients
able to undergo cardioversion as planned and after a significantly
shorter duration of pre-cardioversion anticoagulation (delayed
strategy group),5 thus resulting in higher treatment satisfaction
and cost savings.
Utilizing the TSQM II, significantly higher treatment satisfaction
(Convenience, Effectiveness, and Global satisfaction) was reported
with rivaroxaban, driven by the benefits from the delayed cardiover-
sion group. The X-VeRT trial results, combined with the well-
characterized limitations associated with the VKA therapy, suggest
that use of rivaroxaban in the setting of cardioversion may allow
for more prompt cardioversion and improved patient outcomes.5
The patient preferences in general for novel oral anticoagulants
(including rivaroxaban) over VKAs in AF have been described
previously.17,18 Lane et al. have recently published a consensus
statement on patients’ values and preferences for the management
of arrhythmias, acknowledging that there is an increased drive
towards a patient-centred, symptom-directed management of AF.
It urges that patients’ values and preferences with regard to the
treatment strategy should now be considered as an integral part
of the shared decision-making process.19
The X-VeRT study showed that the number of rescheduled
cardioversions (delayed strategy) owing to inadequate anticoagula-
tion is significantly higher with VKA treatment,5 thus leading to sub-
stantially higher costs. The rescheduling of cardioversions owing to
INR levels outside the therapeutic range remains an issue in parts of
Europe. For example, the British Committee for Standards in
Haematology guidelines state that as many as 25% of procedures
are postponed for this reason,20 although available data suggest
that this could be an underestimate.7 Reducing reschedule rates
on the scheduled day, in addition to removing the need for INR
monitoring, could lead to substantial patient benefits, including a re-
duction in waiting time for cardioversion, time off work, and travel
time. As a consequence, a higher number of patients could be trea-
ted per year owing to reduced costs and waiting times and a reduced
wastage of cardioversion slots.
A recent non-randomized, single-centre, observational study
assessed the potential impact of the use of dabigatran compared
with warfarin on the efficiency of an outpatient cardioversion ser-
vice. A total of 242 cardioversions were performed on 193 patients
over a 36-month period. The authors concluded that 30–40% of
the planned cardioversions were postponed, but that up to 5000
cancellations in the UK could be avoided annually with the use of
dabigatran.18
One limitation of the present study was the relatively small study
population size; however, the reduction seen in the number of can-
celled cardioversions could impact on patient satisfaction and
healthcare system efficiency. Moreover, the present analysis was
restricted to the UK and Italian settings; therefore, these results can-
not be extrapolated to the rest of the world. The TSQM II results
indicated that rivaroxaban seems to be associated with a significantly
higher treatment satisfaction (Convenience, Effectiveness, and
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Table 3 Difference between adjusted means by the
TSQM subscale for rivaroxaban vs. vitamin K antagonist
(intention-to-treat population)
Subscalea Adjusted
mean
95% confidence
interval
P-value
Convenience 13.61 10.89 to 16.33 ,0.001
Effectiveness 4.39 2.62 to 6.15 ,0.001
Global
satisfaction
14.22 11.55 to 16.88 ,0.001
Side-effects 3.32 20.16 to 6.81 0.061
TSQM, Treatment Satisfaction Questionnaire for Medication version II.
aScore scales range from 0 to 100; adjusted means, means adjusted by
cardioversion strategy. If questions 4–6 were ticked as ‘not applicable’, this was
recorded as ‘missing’.
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Table 4 Difference between adjusted means of rivaroxaban and vitamin K antagonist therapy by the cardioversion
strategy (intention-to-treat population)
Subscalea Cardioversion strategy Adjusted mean 95% confidence interval P-value
Convenience Early 11.26 7.32 to 15.20 ,0.001
Delayed 15.96 12.35 to 19.57 ,0.001
Effectiveness Early 2.31 20.14 to 4.76 0.064
Delayed 6.46 3.93 to 8.99 ,0.001
Global satisfaction Early 13.10 9.34 to 16.87 ,0.001
Delayed 15.33 11.62 to 19.04 ,0.001
Side-effects Early 4.10 20.62 to 8.82 0.089
Delayed 2.55 22.64 to 7.74 0.333
aScore scales range from 0 to 100; adjusted means, means adjusted by the cardioversion strategy. If questions 4–6 were ticked as ‘not applicable’, this was recorded as ‘missing’.
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Global satisfaction) compared with VKA therapy. Although the
TSQM II is a widely used generic measure of treatment satisfaction,
the use of a more specific measure (i.e. the Anti-Clot Treatment
Scale) focusing on anticoagulation-specific aspects of treatment sat-
isfaction could potentially lead to a more sensitive evaluation. How-
ever, in patients with DVT, the use of rivaroxaban resulted in
improved treatment satisfaction compared with enoxaparin/VKA
consistently when using both treatment satisfaction measures,
TSQM II and the Anti-Clot Treatment Scale.9
Nevertheless, X-VeRT included a broad patient population,
including oral anticoagulant-naive/untreated and -experienced
patients, in a breadth of clinical situations in the setting of cardiover-
sion in patients undergoing early or delayed cardioversion strategies,
mirroring more accurately the range of patients seen in routine
clinical practice.
Conclusions
The use of rivaroxaban in the setting of elective cardioversion
resulted in greater patient satisfaction and cost savings for the
hospital compared with that of VKA, thus offering the opportunity
for a simplified treatment that could increase patient compliance
and improve efficiency.
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Table 5 Total procedure cost calculations per patient based on inputs
UK Italy
Rivaroxaban Warfarin Rivaroxaban Warfarin
Drug cost for 63 days £13210 £7 (it was assumed that
warfarin is used at 4.5 mg)11
E13212 E413
INR monitoring (63 days) N/A £256a15 N/A E271
Cost of cardioversion £83514 £83514 E676 E662
Additional booked cardioversion procedures per patient–when
rescheduled on the scheduled day
0.172 0.477 0.172 0.477
Additional booked cardioversion procedures per patient–when
rescheduled prior to the scheduled day
0.058 0.161 0.058 0.161
Cost of nurse specialist per rescheduleb £6 £6 N/A N/A
Cost of rescheduling on the scheduled day £145c £401 E116 E316
Cost of rescheduling prior to the scheduled day £0.35 £0.97 N/A N/A
Cost of additional waiting time for patients on warfarin N/A £335,11,14 N/A E35
Total procedure cost per patient £1118 £1539 E924 E1289
INR, international normalized ratio; N/A, not applicable; NHS, UK National Health Service.
aThe INR monitoring required with warfarin was calculated based on weighted average costs taken from NHS reference costs15 for 5.7 visits prior to cardioversion and 4.7 visits
post-cardioversion.
bThe cost for a specialist nurse is based on 7 min per patient to review INR levels and check suitability for cardioversion, which will have to be repeated if the procedure is
rescheduled for a different date. This information has been provided by clinical teams that schedule and perform cardioversion procedures to calculate cost based on NHS nurse
salaries.16
cThe value shown corresponds to the unit cost of cardioversion (£835) plus the cost for nurse rescheduling (£6.07) multiplied by the probability of rescheduling on the scheduled
day (0.172).
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